Tracking Blood Levels Of HIV Improves Treatment Of Infants

May 08, 1997

"Our findings have redefined what's happening to HIV levels in infected infants...Now we can tell which infants are infected shortly after birth and begin treatment immediately."

Scientists at Johns Hopkins and other institutions report that a test that counts AIDS viruses in blood should be routinely used on newborns whose mothers are HIV-positive so that treatment with anti-HIV drugs can be started as early as possible.

The test, until now used only for measuring HIV in adults, offers hope that infants infected with HIV can be identified quickly and their lives extended, perhaps until they are able to respond to newer drug treatments that hold off AIDS indefinitely, according to Thomas C. Quinn, M.D., professor of medicine, molecular microbiology and immunology, and international health.

Based on detecting and measuring the genetic material of HIV in the blood, the test shows within a month after birth whether a baby born to an HIV-positive mother is also infected, according to Quinn. He co-author of a report on a government-funded study published in the May 8 issue of the New England Journal of Medicine. William T. Shearer of Baylor College of Medicine in Houston, Tex., is the principal author.

"Measuring viral RNA in the blood more accurately reflects the level of infection than the usual test that measures anti-HIV antibodies, because most antibodies newborns have are those they get from their mother in the womb," Quinn says. "Until now, doctors had to wait several months before the mothers' anti-HIV antibodies in the baby disappeared and the baby began making its own anti-HIV antibodies."

The ability to track the level of AIDS virus in infants not only lets doctors identify infected infants, but also shows whether babies were infected in the womb during birth, Quinn says. Infants infected in the womb have higher HIV levels when they are born than newborns who get infected only during birth, he explains. By one month of age, babies with low levels of virus tend to be "slow progressors" to AIDS, while those who have high levels may become rapid progressors. The team also found that only about one-fourth of babies born to infected mothers are infected.

Using the test, which measures virus RNA (genetic material) with a technique called polymerase chain reaction, the team found that the pattern of infection in infants differs from the adult pattern. In both infants and adults, the viral levels rise. However, in adults the virus levels fall quickly, while in infants the virus level falls slightly after a few months and remains much higher than in adults, Quinn explains. "These viral kinetics demonstrate why young children die faster with this disease than do adults."

"Our findings have defined what's happening to HIV levels in infected infants," he says.

Quinn said there is no specific level of virus beyond which infants will definitely progress rapidly to AIDS. But in infants with less than 70,000 viruses per milliliter by one month or thereafter, there was no progression.

"This study shows that if you treat babies early and keep their virus load below 70,000 you have a good chance of preventing an early death," says Quinn.

The researchers studied 106 infants for at least one year, or until infants younger than one year died of AIDS. (This study was done was before the discovery that AZT treatment significantly decreased risk of transmitting HIV during pregnancy..) The infants were part of the Women and Infants Transmission Study, funded by the National Institutes of Health.

Other authors of the report include Philip La Russa (Columbia Presbyterian Hospital, New York, N.Y.), Judy F. Lew, Lynne Mofenson and Vincent Smeriglio (National Institutes of Health, Bethesda, Md.), Susan Almy and Leslie Kalish (New England Research Institute, Watertown, Mass.) Kenneth Rich (University of Illinois at Chicago), Edward Handelsman (State University of New York Health Science Center at Brooklyn), Clemente Diaz (University of Puerto Rico, San Juan), and Marcello Pagano (Harvard School of Public Health, Boston, Mass.).


Media Contact: Marc Kusinitz (410)955-8665

Johns Hopkins Medical Institutions' news releases are available on a PRE-EMBARGOED basis on EurekAlert at and from the Office of Communications and Public Affairs'direct e-mail news release service. To enroll, call 410-955-4288 or send e-mail to or

On a POST-EMBARGOED basis find them at,, Newswise at or on CompuServe in the SciNews-MedNews library of the Journalism Forum under file extension ".JHM", Quadnet at or ScienceDaily at

Johns Hopkins Medicine

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to